Should I buy or sell Timber Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares. View TMBR analyst ratings or view top-rated stocks .

When did Timber Pharmaceuticals' stock split?

Shares of Timber Pharmaceuticals reverse split before market open on Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

NYSE:TMBR

Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free TMBR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.34
▼
$2.94
52-Week Range: N/A

Volume: 26,307 shs
Average Volume: 511,937 shs
Market Capitalization: $1.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Social Media

Get Timber Pharmaceuticals alerts:

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About Timber Pharmaceuticals Stock (NYSE:TMBR)

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

Ad Weiss Ratings

The only accurate crypto trading system I know …

Here's what our expert says you should buy before April 14.

TMBR Stock News Headlines

March 10, 2024 | businesswire.com

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

January 28, 2024 | msn.com

Timber Pharmaceuticals Announces Official Name Change

April 19, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

January 13, 2024 | uk.investing.com

Timber Pharmaceuticals Inc (TMBRQ)

November 29, 2023 | finance.yahoo.com

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

November 29, 2023 | finance.yahoo.com

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

November 28, 2023 | tmcnet.com

Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

November 28, 2023 | finance.yahoo.com

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

April 19, 2024 | Weiss Ratings (Ad)

The only accurate crypto trading system I know …

November 21, 2023 | seekingalpha.com

MVST, FBIO and VTVT among mid-day movers

November 17, 2023 | msn.com

Timber Pharmaceuticals files for Chapter 11 in wake of failed merger

November 16, 2023 | msn.com

Timber Pharma slips ahead of shareholder vote on merger

September 18, 2023 | finance.yahoo.com

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

August 29, 2023 | 247wallst.com

HC Wainwright Downgrades Timber Pharmaceuticals

August 28, 2023 | msn.com

HC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)

August 21, 2023 | benzinga.com

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

August 21, 2023 | markets.businessinsider.com

Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher

August 21, 2023 | msn.com

Timber to be taken private by LEO Pharma, stock soars 100%

August 21, 2023 | investorplace.com

Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?

August 21, 2023 | markets.businessinsider.com

US Stocks Mostly Higher; Nasdaq Jumps 100 Points

August 21, 2023 | marketwatch.com

Timber Pharmaceuticals Shares Soar on Takeover by LEO Pharma

August 21, 2023 | benzinga.com

Why Timber Pharmaceuticals Stock Is Skyrocketing Today

August 21, 2023 | finance.yahoo.com

LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals

August 21, 2023 | finance.yahoo.com

Timber Pharmaceuticals to be Acquired by LEO Pharma

August 15, 2023 | morningstar.com

Timber Pharmaceuticals Inc Ordinary Shares

July 3, 2023 | finance.yahoo.com

Timber Pharmaceuticals Discloses Communication From NYSE American

June 5, 2023 | msn.com

Timber Pharmaceuticals Soars as FDA Removes Hurdle

See More Headlines

Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:TMBR
CUSIP: N/A
CIK: 1504167
Web: www.timberpharma.com
Phone: (973) 314-9577
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -511.45%
Return on Assets: -180.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.50
Quick Ratio: 0.50

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.79 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 3,430,000
Free Float: 3,378,000
Market Cap: $1.21 million
Optionable: Not Optionable
Beta: 0.03

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. John Koconis M.B.A. (Age 53)
Chairman, CEO & President
Comp: $570.19k
Mr. Joseph Lucchese (Age 56)
Executive VP, CFO, Treasurer & Secretary
Comp: $542.3k
Dr. Alan Mendelsohn M.D. (Age 60)
Executive VP & Chief Medical Officer
Comp: $507.16k

Key Competitors

View All Competitors

TMBR Stock Analysis - Frequently Asked Questions

Should I buy or sell Timber Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares.
View TMBR analyst ratings or view top-rated stocks.
When did Timber Pharmaceuticals' stock split?: Shares of Timber Pharmaceuticals reverse split before market open on Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

This page (NYSE:TMBR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis

About Timber Pharmaceuticals Stock (NYSE:TMBR)

TMBR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TMBR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info